Experimental drug targets Low-Oxygen tumors in prostate cancer
NCT ID NCT06836726
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether adding evofosfamide to standard hormone therapy can help men with castration-resistant prostate cancer that has spread. The drug targets low-oxygen areas in tumors. 35 participants will receive the drug combination and be monitored for PSA response and tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Evofosfamide (a drug that targets low-oxygen areas in tumors)
What this could lead to
If successful, this could provide a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is a small, early-phase trial with only 35 participants. The drug may not improve outcomes and could cause side effects like bone marrow suppression or fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Margaret Cancer Center
Toronto, Ontario, M7A 2S4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••